Scope and Claims of US Patent 10,201,517 (Topical Brimonidine Gel) and the US Patent Landscape
US Patent 10,201,517 claims a specific topical gel formulation built around (i) brimonidine (or brimonidine tartrate) in a defined strength range, (ii) two preservatives (methylparaben and phenoxyethanol), (iii) a carbomer gelling agent with an expressed relationship to methylparaben concentration, and (iv) a controlled polyol system (total polyol or defined propylene glycol plus glycerol) in a defined pH window. The claims are drafted to capture both broad gel formulations and narrower “carrier chemistry” embodiments (specific carbomer types; specific propylene glycol/glycerol system; optional titanium dioxide).
What is the claim scope of US 10,201,517 for topical brimonidine gel formulations?
Featured snippet answer: The patent protects topical brimonidine gel compositions meeting strict, co-located constraints on actives, preservatives, carbomer, polyol content, and pH, including a nonlinear formulation rule: when methylparaben > 0.15%, carbomer < 1.25%.
Core claim elements (Claim 1 as the anchor)
Claim 1 requires all of the following:
- Brimonidine component
- 0.05% to 5% (w/w) brimonidine or brimonidine tartrate.
- Preservative system
- Methylparaben: 0.1% to 0.20% (w/w)
- Phenoxyethanol: 0.3% to 0.4% (w/w)
- Gelling agent
- Carbomer: 0.80% to 1.50% (w/w)
- Plus the key conditional limitation:
- If methylparaben > 0.15%, then carbomer < 1.25%.
- Polyol system
- Total polyol: 9.0% to 13.0% (w/w) (not limited to specific polyols in Claim 1)
- pH
- Combination of constraints matters
- Claim 1 is not just a “brimonidine gel” claim; it is a constrained formulation matrix that forces a defendant to land inside a narrow numeric box across multiple ingredients.
Why the methylparaben–carbomer relationship is a meaningful design-around target
The conditional limitation is a high-value claim feature:
- If a formulation uses methylparaben above 0.15%, it must keep carbomer below 1.25% to remain inside Claim 1.
- A generic or branded competitor trying to avoid infringement would look for either:
- methylparaben ≤ 0.15%, while keeping carbomer higher, or
- methylparaben > 0.15% with carbomer at or above 1.25% (to argue non-infringement if the literal reading is enforced that way).
From a litigation scope perspective, this is the kind of “formulation rule” courts often treat as a clear numeric limitation, not an “obvious optimization” feature.
How broad are the dependent claims (2–7) relative to Claim 1?
Featured snippet answer: Dependent claims narrow Claim 1 by specifying the polyol composition (defined split), carbomer grade, and optional titanium dioxide, plus tighter ranges on some components and a more defined pH adjustment method.
Claim 2: Polyol split constraint
Claim 2 narrows Claim 1 by requiring:
- Total polyol includes:
- About 4.5% to 6.5% (w/w) of a first polyol, plus one or more additional polyols.
This moves from a total-polyol requirement to a two-part composition structure, leaving some flexibility (the patent does not define which polyol is the “first polyol,” in the claim text provided).
Claim 3: Carbomer grade selection
Claim 3 narrows “carbomer” to one of:
- carbomer 934P
- carbomer 974P
- carbomer 980
This is a classic narrowing dependent claim. A competitor could attempt to use other carbomers outside that list to reduce literal infringement exposure, depending on whether other carbomer grades are “carbomer [number]” in a literal sense.
Claim 4: A specific formulation “recipe” with tighter ranges and sodium hydroxide pH adjustment
Claim 4 narrows with:
- Brimonidine tartrate: 0.1% to 0.6%
- Methylparaben: 0.1% to 0.15%
- Phenoxyethanol: 0.3% to 0.4%
- Carbomer: 0.80% to 1.50%
- Propylene glycol: 4.5% to 6.5%
- Glycerol: 4.5% to 6.5%
- Purified water
- pH: 5.0 to 6.5, adjusted with sodium hydroxide aqueous solution.
Key scope implications:
- Claim 4 fixes the polyol identity and approximate amounts (propylene glycol + glycerol) inside the total polyol framework of Claim 1.
- Claim 4 also fixes pH tighter than Claim 1 and adds a method-of-manufacturing-style detail (pH adjusted by NaOH solution). In infringement analysis, “adjusted by an adequate amount of sodium hydroxide aqueous solution” can matter if a competitor achieves pH by another base.
Claim 5: Phenoxyethanol elevated threshold
Claim 5 narrows Claim 4 by adding:
- Phenoxyethanol > 0.3% (w/w)
So Claim 5 excludes phenoxyethanol at the lower edge of Claim 4’s range.
Claim 6: Optional titanium dioxide at a defined dispersed level
Claim 6 narrows Claim 5 by requiring:
- Water dispersible titanium dioxide: 0.04% to 0.08%
If the competitor’s product omits TiO2, it can fall outside Claim 6 (depending on whether it still infringes earlier claims like Claim 4 or Claim 1; dependent claims only matter if all prior limitations are met).
Claim 7: Standalone “TiO2 included” formulation with fixed pH window
Claim 7 requires:
- Brimonidine tartrate: 0.1% to 0.6%
- Methylparaben: 0.1% to 0.15%
- Phenoxyethanol: 0.3% to 0.4%
- Carbomer: 0.80% to 1.50%
- Propylene glycol: 4.5% to 6.5%
- Glycerol: 4.5% to 6.5%
- Water dispersible TiO2: 0.04% to 0.08%
- Purified water
- pH: 5.0 to 6.5 (no explicit NaOH method recited in Claim 7).
Claim 7 is useful for enforcement because it captures a TiO2-bearing gel without tying the pH adjustment method to NaOH.
How does claim structure translate into infringement risk for different competitor gel formulations?
Featured snippet answer: Risk tracks whether a competitor’s product hits the full set of numeric limitations in one claim, especially the combined constraints on methylparaben + carbomer + preservatives + polyols + pH.
Scenario map (literal infringement screening)
- If a competitor uses brimonidine tartrate in-range but changes preservatives or pH
- It will often exit Claim 1 immediately (phenoxyethanol fixed; pH broad but still bounded).
- If a competitor uses a different preservative system
- Claim 1 requires methylparaben and phenoxyethanol at defined ranges.
- If a competitor uses a carbomer outside 0.80% to 1.50%
- If a competitor uses methylparaben > 0.15%
- It must keep carbomer < 1.25% to remain inside Claim 1; staying outside provides an easy design-around.
- If a competitor uses propylene glycol/glycerol at non-matching levels
- It can stay outside Claims 4–7 while potentially still hitting Claim 1 (because Claim 1 uses “total polyol” not the split).
- If a competitor omits TiO2
- It may avoid Claims 6–7 but still be exposed under Claims 1–5.
What patents likely define the prior art and obviousness boundaries around US 10,201,517?
Featured snippet answer: Without full document metadata for US 10,201,517’s specification, prosecution history, and cited references, the only defensible landscape summary here is at the claim-feature level. The relevant prior art categories are predictable: brimonidine topical gels, carbomer-based brimonidine formulations, and preservative/polyol systems for topical ophthalmic/dermal gels.
Claim-feature clustering that prior art tends to cover
- Topical brimonidine compositions (often for ocular or skin indications; formulation variants are common)
- Carbomer gels with brimonidine
- Preservative bundles using methylparaben and phenoxyethanol
- Polyol/tuning agents such as propylene glycol and glycerol in gel matrices
- pH windows compatible with brimonidine salt stability and skin tolerability
Where US 10,201,517 is likely to be strongest (claim novelty points)
- A tight and unusual combination of:
- methylparaben and phenoxyethanol at fixed narrow ranges,
- total polyol 9–13%,
- pH 4.5–7.5 (broad in isolation, but constrained with the other components),
- and especially the conditional carbomer limitation based on methylparaben concentration.
Where US 10,201,517 can be vulnerable (based on claim drafting)
- If the prior art already disclosed a broad brimonidine gel with methylparaben/phenoxyethanol/carbomer/polyols, the remaining fight is whether the specific numeric interlocks were not disclosed and would not have been obvious.
- Dependent claims tied to specific carbomer grades and a specific polyol split are narrower and may track manufacturing availability rather than patentable chemistry.
What US drug regulatory status matters for enforcement timing of formulation patents?
Featured snippet answer: Enforcement exposure typically aligns with whether the patented formulation is an FDA-approved product (NDA/ANDA) versus an unapproved topical product. Formulation patents can still be asserted in the US regardless of Orange Book listings, but Paragraph IV dynamics are only relevant if a listed Orange Book patent is tied to an ANDA AND the product is an FDA “reference listed drug” ecosystem.
At this point, the provided information does not include:
- the drug product name associated with US 10,201,517,
- any Orange Book listing,
- any FDA application number,
- or any litigation case.
Because the prompt requires a detailed landscape for infringement and exclusivity, those missing linkages determine the relevance of Paragraph IV, settlement, and generic entry risk.
How can competitors design around the claims of US 10,201,517?
Featured snippet answer: The claims present multiple “escape hatches” because each claim requires a multi-parameter match.
High-probability design-around levers
- Preservatives
- Replace methylparaben or phenoxyethanol, or move outside their numeric ranges.
- Methylparaben–carbomer conditional limitation
- If using methylparaben > 0.15%, keep carbomer at or above 1.25% to exit Claim 1.
- Polyol composition
- For Claims 4–7, avoid the propylene glycol + glycerol ratio/ranges.
- Carbomer grade
- For Claim 3, use a different carbomer (not 934P/974P/980) or one not literally listed.
- pH
- Move outside the pH windows (Claim 1: 4.5–7.5; Claims 4/7: 5.0–6.5).
- NaOH pH adjustment
- For Claim 4 only, adjust using a different base (depending on how proof is handled in litigation).
- TiO2
- Remove titanium dioxide to avoid Claims 6 and 7.
What is the likely role of US 10,201,517 in a broader brimonidine gel patent estate?
Featured snippet answer: US 10,201,517 is a formulation claim that typically functions as either:
- a core “composition of matter” style protection around the marketed gel, and/or
- a secondary claim layer that blocks generic reformulation unless the competitor changes critical formulation variables.
In most formulation-heavy topical products, estates also include:
- method-of-treatment/use claims,
- additional preservative/polyol/carrier variations,
- particle or dispersion stability approaches (for TiO2 or other additives),
- and sometimes manufacturing or stability-related claims.
But a complete landscape requires the actual related US patents (family members, continuations, continuation-in-part, and any listed patents tied to specific FDA applications), which is not provided in the prompt.
Key takeaways on scope and landscape for US 10,201,517
- Claim 1 is the broadest enforceable anchor: brimonidine + methylparaben + phenoxyethanol + carbomer + polyol total + pH, with a conditional carbomer cutoff tied to methylparaben concentration.
- Claims 4 and 7 define a tighter “propylene glycol + glycerol” gel architecture with pH 5.0–6.5; Claim 4 adds a NaOH pH adjustment requirement.
- Claims 6 and 7 add TiO2 in a defined dispersed amount; omitting TiO2 can avoid those dependent claims but may not avoid Claim 1.
- Claim 3 restricts carbomer grades to 934P/974P/980, creating a straightforward literal design-around if other carbomers are used.
- A competitor’s primary infringement risk comes from whether its product’s formulation lands inside the same numeric grid across all required components.
FAQs
1) How does the “methylparaben >0.15% implies carbomer <1.25%” limitation affect non-infringement strategies?
It creates a direct numeric design-around: formulations that use methylparaben above 0.15% can reduce exposure by keeping carbomer at or above 1.25% (or by using methylparaben at or below 0.15% while retaining carbomer in a higher band).
2) Can a product infringe Claim 4 if it uses the same ingredient types but a different base for pH adjustment?
If the pH adjustment is not performed with “sodium hydroxide aqueous solution” as recited in Claim 4, the product can fall outside Claim 4 while still potentially implicating other claims that do not require the NaOH method (notably Claim 1 and Claim 7).
3) What formulation changes most often move a topical gel outside Claim 1?
Changing either preservative system (methylparaben and/or phenoxyethanol), moving carbomer outside 0.80% to 1.50%, or moving pH outside 4.5 to 7.5 are frequent exits.
4) If a generic omits titanium dioxide, does it avoid the entire patent?
Omitting TiO2 can avoid dependent claims that require TiO2 (Claims 6–7). Exposure may still remain under the broader claims (1–5), which do not require TiO2.
5) Which claim is most useful for blocking competitors that match the “exact marketed recipe”?
Typically Claim 4 or Claim 7 because they specify the full narrow recipe: brimonidine tartrate range, methylparaben/phenoxyethanol ranges, carbomer range, propylene glycol and glycerol ranges, TiO2 inclusion (Claim 7), and pH 5.0–6.5.
References (APA)
- US Patent 10,201,517.
